Clinical study on ambroxol combined with pirfenidone in treatment of pulmonary interstitial fibrosis
Objective To observe the clinical effect of ambroxol hydrochloride combined with pirfenidone in treatment of pulmonary interstitial fibrosis. Methods Patients (80 cases) with pulmonary interstitial fibrosis in Tianjin Teda Hospital from September 2020 to January 2024 were divided into control and treatment group by random number table method,and each group had 40 cases. Patients in the control group were po administered with Pirfenidone Tablets,200 mg/time,three times daily,increase by 0.2 g each time within 2 weeks until 0.6 g/time. Patients in the treatment group were po administered with Ambroxol Hydrochloride Talets on the basis of the control group,30 mg/time,three times daily. Patients in two groups were treated for 3 months. After treatment,the clinical evaluations were evaluated,the levels of TNF-α,osteopontin,IL-13,CXCL14,LPO,GSH-Px,CAT,VCAM-1,IGF-Ⅰ,LN,TLC,SaO2,MMF and DLCO,and the scores of ATAQ-IPF and SGRQ in two groups before and after treatment were compared. Results After treatment,the total effective rate in the treatment group was 97.50％,which was significantly higher than that in the control group (80.00％),and the difference between the two groups was statistically significant (P<0.05). After treatment,the levels of TNF-α,osteopontin,IL-13,CXCL14,LPO,VCAM-1,IGF-Ⅰ,and LN in two groups were significantly decreased compared with before treatment,while the levels of GSH-Px,CAT,TLC,SaO2,MMF,and DLCO were significantly increased compared with before treatment (P<0.05),and the levels of these indicators in the treatment group were significantly improved compared with the control group (P<0.05). After treatment,the SGRQ scores of patients in two groups were increased compared with before treatment,while the ATAQ-IPF scores were decreased (P<0.05). The SGRQ and ATAQ-IPF scores in the treatment group were significantly improved compared with the control group (P<0.05). Conclusion Ambroxol hydrochloride combined with pirfenidone in treatment of pulmonary interstitial fibrosis can reduce oxidative stress and inflammatory damage,reduce pulmonary fibrosis,improve respiratory status,and enhance lung function,clinical efficacy and quality of life.
NETL
NSTL
万方数据
